A systematic review and meta-analysis assessing adverse event profile and tolerability of nicergoline.
Bottom Line: Incidence of any adverse events (AEs) was slightly higher (RR=1.05; 95% CI 0.93 to 1.2) while incidence of serious AEs was lower (RR=0.85; 95% CI 0.50 to 1.45) in the nicergoline compared with placebo group.Frequency of anxiety was significantly lower in nicergoline as compared with placebo (p=0.01).Other AEs including diarrhoea, gastric upset, dizziness and drowsiness were less frequent in the nicergoline group when compared with placebo/active drugs, but the difference was non-significant.
Affiliation: Department of Neurology and Psychiatry, University Hospital, Umberto I, University of Rome, Sapienza, Italy.Show MeSH
Related in: MedlinePlus
Mentions: Higher risk of fatigue was associated with nicergoline compared with active comparators including ergot derivatives but the difference was non-significant. Higher risk of hot flushes was reported with nicergoline compared with other comparators. Risk of headache and hypotension was higher with nicergoline compared with placebo. Higher risk of insomnia and itching was reported with nicergoline. For none of the AEs, where risk was higher for the nicergoline group, was any significant difference observed compared with the other intervention or placebo (figure 3).
Affiliation: Department of Neurology and Psychiatry, University Hospital, Umberto I, University of Rome, Sapienza, Italy.